THOMAS ANDREW,BAUMANN KARLHEINZ,GREEN LUKE,LIMBERG ANJA,LUEBBERS THOMAS
申请号：
NZ61252512
公开号：
NZ612525A
申请日:
2012.02.28
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Provided are bridged piperidine derivative compounds of general formula (I), where the variables are as defined in the specification. Examples of the compounds include [(rac)-3-exo-8-(2-Chloropyridin-4-yl)-8-aza-bicyclo [3.2.1 ] oct-3-yl]-[8-(3,4-difluorophenyl)-6-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine and 2-{ 6-(4-Chloro-benzyl)-2-[(rac)-3-endo-8-(3-methyl-[1,2,4]thiadiazol-5-yl)-8-azabicyclo[3.2.1] oct-3-ylamino]-pyrimidin-4-yl} -propan-2-ol. The compounds are modulators of amyloid beta and may be useful in the treatment or prevention of Alzheimer&rsquo；s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome. Further provided are tablet and capsule formulations comprising the compounds.
